Nonresponse to 18-month lamivudine monotheraphy in chronic hepatitis B patients with dual genotype B and C infection and acute exacerbation

Ming Jen Sheu, Ching Yih Lin, Chi Shu Sun, Hsing Tao Kuo, Lok Beng Koay, Chuan Lee, Jyh Jou Chen, Ling Yu Tang, Sun Lung Tsai*

*Corresponding author for this work

Research output: Contribution to journalJournal Article peer-review

3 Scopus citations

Abstract

Molecular epidemiologic studies have indicated the possible existence of mixed infection of different hepatitis B virus (HBV) genotypes in chronic hepatitis B (CH-B) carriers, but the effect of dual HBV genotype B and C infection on the efficacy of lamivudine therapy remains unclear. We report four CH-B patients with dual HBV genotype B and C infection and acute exacerbation who received lamivudine monotherapy for about 18 months. None of them had achieved a sustained response at the end of the 18-month trial of treatment.

Original languageEnglish
Pages (from-to)588-593
Number of pages6
JournalJournal of the Formosan Medical Association
Volume105
Issue number7
DOIs
StatePublished - 07 2006
Externally publishedYes

Keywords

  • Acute exacerbation
  • Chronic hepatitis B
  • Dual genotype infection
  • Hepatitis B virus
  • Lamivudine therapy
  • Sustained response

Fingerprint

Dive into the research topics of 'Nonresponse to 18-month lamivudine monotheraphy in chronic hepatitis B patients with dual genotype B and C infection and acute exacerbation'. Together they form a unique fingerprint.

Cite this